Tumor Composition of Melanoma Indicates Potential Responses to Immunotherapy
Sushant Patkar, a computer science graduate student in the NCI-UMD Partnership for Integrative Cancer Research program, co-authored a paper in the journal Cell that found that the genetic diversity of mutations in a melanoma tumor may be a critical factor in why some melanomas respond better to immunotherapy than others. The results hint at which melanoma patients could benefit from immunotherapy.
